Sodium Valproate

Debate between Cat Smith and Bob Blackman

Thursday 29th October 2026 Commons Chamber

[Cat Smith (Lancaster and Wyre) (Lab)]

It is not the first time that I have had an Adjournment debate on sodium valproate in my 11-and-a-bit years as a Member of Parliament. It continues to be an issue that affects so many, and for which justice still feels so far away.

Given the history of this House debating the topic, I do not intend to spend much time going over the history of the drug, which has been used to treat epilepsy and bipolar disorder since the early 1970s. For the benefit of anyone who is tuning in for the first time, I will go over the brief facts of what happened. The drug is teratogenic and was known to be teratogenic from the time it was first licensed. Despite that, doctors were initially advised that the risk did not justify

“discouraging a woman who needs anticonvulsant treatment from having a child or changing a satisfactory drug regimen when the epilepsy is well controlled.”

The result has been that we have been playing catch-up ever since, with the Valproate Pregnancy Prevention Programme only being launched in 2018, following tireless campaigning from women affected, such as my constituent Janet Williams—who is in the Public Gallery—and her friend and colleague Emma Murphy.

It is difficult to calculate the number of children exposed to valproate in utero since its 1973 licensing. The Patient Safety Commissioner has made an estimate of around 14,000 for the period from 1972 to 2017 in England. Diagnosis often gets picked up when clinicians, or in some cases parents, recognise facial dysmorphic features. Children born with foetal valproate spectrum disorder can have a wide range of physical and mental health symptoms, including but not limited to weak muscles, visual problems, hearing difficulties, difficulties with balance, social anxiety, low energy, heightened sensitivity to noise and difficulties in regulating emotions. One of the biggest health conditions facing people with foetal valproate spectrum disorder is autism. A significant number also have attention deficit hyperactivity disorder, or ADHD, dyspraxia, sensory processing disorder and epilepsy.

It can affect children in very different ways. In some of the most severe cases—I know that the hon. Member for Harrow East (Bob Blackman) has a constituent who is very severely affected—the individual can end up bedbound and very severely disabled. For some children, autism and sensory processing may be more of an issue.

[Bob Blackman (Harrow East) (Con)]

I thank the hon. Member for introducing this long-awaited debate. I have a constituent, Karen Buck, whose daughter, Bridget Doyle, was born paralysed, is bedbound and suffers from autism. The reality is that there are many victims out there who suffer from a variety of conditions, as the hon. Lady quite rightly points out—not least spina bifida, which she has not mentioned. The problem here is that legal aid for the court case, which was established to try to get recompense for those victims, was withdrawn some 20 years ago. Unfortunately, although commitments have been made time and again to help these people, these mothers are now advanced in age, and the children they have supported will desperately need support when their lives end. Does the hon. Lady think there is now a need for a proper compensation scheme?